Needham & Company LLC Reaffirms “Buy” Rating for CRISPR Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. They currently have a $84.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 93.15% from the stock’s […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. They currently have a $84.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 93.15% from the stock’s […]
